Business Context and Reporting Period
This Form 8-K reports on the 2025 Annual Meeting of Stockholders held by Impact Biomedical Inc. on November 5, 2025. The company is incorporated in Nevada and its common stock (Ticker: IBO) is listed on the NYSE American LLC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
A total of 64,328,010 shares, representing 88.50% of eligible shares, were present at the meeting, constituting a quorum. The following matters were approved:
- Director Elections: Stockholders approved the election of eight directors: Frank D. Heuszel, Elise Brownell, Melissa Sims, Castel Hibbert, David Keene, Christian Zimmerman, Jason Grady, and Chan Heng Fai Ambrose.
- Auditor Ratification: Stockholders ratified the appointment of Grassi & Co. Certified Public Accountants, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Executive Compensation: Stockholders approved, on an advisory basis, the compensation of the named executive officers.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting outcomes.
Key Facts for Investor Verification
- Verify the full voting breakdown for each director nominee, noting that while all were approved, vote counts varied slightly among candidates.
- Confirm the tenure of the newly elected directors, which extends until the next Annual Meeting of shareholders.
- Review the upcoming fiscal year-end (December 31, 2025) financial reports to assess the company's financial health, as no metrics were included in this filing.
- Note the presence of 2,702,761 broker non-votes on the director elections and executive compensation advisory vote.